Citations

Clear

1053 citation(s) found for "Andre, F".

PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Carvo, Ingrid, Lampron, Megan E., Albigès, Laurence , Stanton, Melissa, Freeman, Gordon J. , Hirsch, Michelle S. , Callea, Marcella , Ho, Thai H. , McDermott, David F. , Atkins, Michael B. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4526-4526

10.1200/jco.2014.32.15_suppl.4526 Get It

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).
Renfro, Lindsay A. , Haller, Daniel G. , Loprinzi, Charles L. , Twelves, Chris, Group, Adjuvant Colon Cancer Endpoints (ACCENT), Grothey, Axel , Kerr, David , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Yothers, Greg , Sargent, Daniel J. , Group, Adjuvant Colon Cancer Endpoints (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2014.32.15_suppl.3601 Get It

Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.
Thibodeau, Stephen N. , Gallinger, Steven , Monges, Geneviève, Pogue–Geile, Katherine L. , Roth, Arnaud, Pavey, Emily S., Kim, George P., Group, ACCENT Collaborative, Sargent, Daniel J. , Shi, Qian , Yothers, Greg , Tejpar, Sabine , Bertagnolli, Monica M. , André, Thierry , Labianca, Roberto , Hamilton, Stanley R. , Paik, Soonmyung , Klingbiel, Dirk , Sinicrope, Frank A. , Group, ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3507-3507

10.1200/jco.2014.32.15_suppl.3507 Get It

Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.
Salem, Mohamed E. , Yin, Jun , Goldberg, Richard M. , Pederson, Levi , Grothey, Axel, Gramont, Aimery de , Wolmark, Norman , Alberts, Steven R. , Taı̈eb, Julien , Marshall, John L , Lonardi, Sara , Yoshino, Takayuki , Kerr, Rachel , Yothers, Greg , André, Thierry , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 728-728

10.1200/jco.2018.36.4_suppl.728 Get It

728 Background: Adjuvant FOLFOX therapy for stage II patients remains controversial, and selection criteria are imprecise. We examined the trend of disease-free survival (DFS: time to recurrence or death, whichever occurs first); time to recurrence (TTR: time to recurrence, censored at death without recurrence); survival after recurrence (SAR); and overall survival (OS) of pts treated with FOLFOX over a ten-year period. Methods: Outcomes of pts with stage II colon cancer enrolled in 6 adjuvant trials receiving FOLFOX alone were analyzed. Pt enrollment period was dichotomized as old (1998 – 2003) vs. new era (2004 – 2009) based on the FDA approval date of bevacizumab. 3/5yr event-free rates were estimated using adjusted Kaplan-Meier methods. Outcomes were compared between the two eras by multivariate Cox model. To control for potential confounding effects, all analyses were adjusted for age, gender, performance score, T stage, number of lymph nodes (LNs) examined, tumor side, and histologic grade. Results: In total, 1,122 pts with stage II were identified; 71% and 29% were treated in the old and new era, respectively. Pts enrolled in the new era were significantly younger and more likely to have higher tumor-grade and right-sided tumors compared to old era. More pts in the new era (71%) had ≥12 LNs examined compared to the old era (53%). After adjusting for potential confounding effects, no difference in DFS, TTR, SAR or OS between old and new eras was found (Table). Although median SAR increased from 13.6 to 26 months over time, this was not statistically significant, likely due to lack of power. An increased TTR over time (HRadj. 0.41, padj.= 0.002) was observed in pts with ≥12 LNs examined (3-yr TTR: 92% in old era vs. 96% in new era), but not pts with <12 LNs examined (pinteraction = 0.04). Conclusions: In stage II colon cancer pts who received adjuvant FOLFOX, no significant increase of DFS or OS was observed over time. However TTR was longer only in pts with ≥12 LNs examined. [Table: see text]
Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.
Salem, Mohamed E. , Yin, Jun , Goldberg, Richard M. , Pederson, Levi , Grothey, Axel, Gramont, Aimery de , Wolmark, Norman , Alberts, Steven R. , Taı̈eb, Julien , Marshall, John L , Lonardi, Sara , Yoshino, Takayuki , Kerr, Rachel , Yothers, Greg , André, Thierry , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 724-724

10.1200/jco.2018.36.4_suppl.724 Get It

724 Background: Adjuvant FOLFOX is the standard of care for pts with stage III colon cancer and a platform to test new agents. Improvements in supportive care and development of newer treatments for metastatic disease impact the overall outcome of pts treated with adjuvant therapy. We examined the trend of disease-free survival (DFS), survival after recurrence (SAR), and overall survival (OS) of pts treated with FOLFOX over a ten-year period. Methods: Outcomes of colon cancer pts enrolled in 6 adjuvant trials receiving FOLFOX alone were analyzed. Pt enrollment period was dichotomized as old (1998 – 2003) vs. new era (2004 – 2009) based on the FDA approval date of bevacizumab. 3/5yr event-free rates were estimated by adjusted Kaplan-Meier methods. Outcomes were compared between the two eras by Cox model. To control for potential confounding effects, all analyses were adjusted for age, gender, performance score, T/N stage, tumor sidedness and histologic grade. Results: In total, 7,230 pts (stage II [n = 1122]; stage III [n = 6,108]) were identified; 32% and 68% were treated in the old and new era, respectively. Stage III pts enrolled in the new era were significantly younger, more likely to have T4/N2 disease, higher tumor grade, and left-sided tumors. After adjusting for pt characteristics, no difference in DFS was seen over time. However prolonged SAR and OS were observed in pts treated in the new era (Table). 5yr OS increased from 76% to 80% over time. Median SAR improved from 14.8 to 26.4 months. Conclusions: Stage III colon cancer pts who received adjuvant FOLFOX experienced significant improvements in SAR and OS—but not DFS—over time. In view of the improvements in OS and nearly doubled SAR, the optimal duration of OS follow-up to evaluate the benefits of adjuvant therapy (currently 5 years) should be reassessed, and ACCENT investigators are planning to conduct these additional analyses using their large pooled-trial database. [Table: see text]
Health Care Evolves From Reactive to Proactive
Waldman, Scott A. , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 31, 2018 | Volume: 105 | Issue: 1 | Pages: 10-13

10.1002/cpt.1295 | PMID 30597564 Get It

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
Quiroz, Yakeel T. , Albensi, Benedict C. , Astell, Arlene , Babiloni, Claudio , Bahar‐Fuchs, Alex , Bowman, Gene L. , Chételat, Gaël , Ciro, Carrie , Cohen, Ann D. , Dilworth‐Anderson, Peggye, Dreux, Simone, Edland, Steven D. , Esbensen, Anna J. , Ewers, Michael , Fargo, Keith N. , Fortea, Juan , González, Héctor M. , Gustafson, Deborah , Head, Elizabeth , Hendrix, James A. , Hofer, Scott M. , Johnson, Leigh , Jutten, Roos J. , Kilborn, Kerry, Martins, Ralph N. , Morris, Martha Clare , Murray, Melissa E. , Parra, Mario A. , Roe, Catherine M. , Santos, Octavio A. , Scarmeas, Nikolaos , Schneider, Lon S. , Schupf, Nicole , Sikkes, Sietske A.M. , Snyder, Heather M. , Sohrabi, Hamid R. , Strydom, André , Muñiz‐Terrera, Graciela , Teunissen, Charlotte E. , Lent, Debora Melo van , Weinborn, Michael , Wesselman, Linda M.P. , Arenaza-Urquijo, Eider, Teunissen, Charlotte E , Fortea, Juan , Murray, Melissa E , Babulal, Ganesh M. , Arenaza‐Urquijo, Eider M. , Bell, J. Simon , Brickman, Adam M. , Dodge, Hiroko Hayama , Evered, Lisbeth Anne , Gonzalez, Hector M , Lanctôt, Krista L. , Manly, Jennifer J. , Mielke, Michelle M. , Oh, Esther S , Rissman, Robert A. , Stern, Yaakov , Tang, Yi , Wilcock, Donna M. , Zetterberg, Henrik , O’Bryant, Sid E. , Head, Elizabeth , Cohen, Annie

Mayo Clinic

Alzheimer's & Dementia | December 13, 2018 | Volume: 15 | Issue: 2 | Pages: 292-312

10.1016/j.jalz.2018.09.009 | PMID 30555031 Get It

Abstract Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART ) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross‐PIA white paper that provides both a concise “state‐of‐the‐science” report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
Office-Based Mesenchymal Stem Cell Therapy for the Treatment of Musculoskeletal Disease: A Systematic Review of Recent Human Studies
Law, Luke, Wijnen, André J. van , Eldrige, Jason S. , Mauck, William D. , Pingree, Mathew J., Yang, Juan , Muir, Casey W, Erwin, Patricia J., Bydon, Mohamad , Qu, Wenchun , van Wijnen, Andre J , Hunt, Christine , Nassr, Ahmad , Larson, A. Noelle , Muir, Casey

Mayo Clinic

Pain Medicine | December 3, 2018 | Volume: 20 | Issue: 8 | Pages: 1570-1583

10.1093/pm/pny256 | PMID 30597057 Get It

Abstract Background The use of mesenchymal stem cells (MSCs) in clinical applications for the treatment of musculoskeletal disease is steadily increasing in office-based practice. The so-called “first generation” of MSCs is defined as autologous stem cells that have undergone minimal manipulation and are used for a homologous purpose. Systematic reviews of the clinical trials completed to date of such MSCs enable practitioners to better understand what is currently known about the outcomes and side effects of such treatments. Study Design A systematic review of human clinical studies of office-based MSC therapy for the treatment of painful degenerative musculoskeletal conditions. Methods A search of the Ovid MEDLINE, EMBASE, and Scopus databases was conducted from 2006 through September 2016. Seven hundred sixty-one records were identified from database searching, and two records from reference review of included papers. Studies with human subjects that evaluated treatment of musculoskeletal disease with minimally manipulated MSCs were included. Results Eight studies were included in this review based on selection criteria. A total of 941 patients were included, 841 of whom received cellular products, and no significant adverse events were reported. Symptomatology generally improved, though no differences were seen over controls where present. Conclusion Support in the literature is strongest for the use of bone marrow aspirate concentrate (BMAC) injections for the treatment of knee pain, but applications of the use of BMAC and peripheral blood–derived MSCs for the treatment of hip pain, tendon pain, and disc pain have all been reported. Further research is required, with large randomized controlled trials.